About Us

EVDL is a Hong Kong homegrown start-up formed by medical doctors, experienced scientists and engineers having the vision and passion in providing solutions to unmet medical needs. With a unique integration of expertise of our multidisciplinary professionals, from scientific research to manufacturing, we are able to transfer knowledge to innovative yet practical diagnostic solutions to the community. As part of the Avalon Biomedical (Management) Limited, a local biotechnology incubator, we aspire to become a worldwide leader in diagnostic industry and to push Diagnosis beyond Boundaries!

EVDL is a Hong Kong homegrown start-up formed by medical doctors, experienced scientists and engineers having the vision and passion in providing solutions to unmet medical needs. With a unique integration of expertise of our multidisciplinary professionals, from scientific research to manufacturing, we are able to transfer knowledge to innovative yet practical diagnostic solutions to the community. As part of the Avalon Biomedical (Management) Limited, a local biotechnology incubator, we aspire to become a worldwide leader in diagnostic industry and to push Diagnosis beyond Boundaries!

Milestone

2015

Project Start &
Design Phase

July

Emerging Viral Diagnostics (HK) Limited (“EVDL”) was founded

The core research team is formed by famous scientists, doctors, experienced biotechnologists and engineers as well as technical and technology investors.

Nov

Establishment of Respiratory Virus Research Foundation

HKU and PolyU jointly announced the establishment of “Respiratory Virus Research Foundation”. EVDL and the research team from the Universities immediately kickstarted related virus and translational research work.

2018

Establishment of Prototype Machine &
Biochemistry Reagents

Dec

Successfully Detected Samples

Successful detection of clinical samples in Queen Mary Hospital (QMH). Design of prototype machine and biochemistry reagents established and with more optimization work in the pipeline.

2020

First Introduction of the EVDL System to the Public

JAN

Demonstrated the strength as Platform Technology during outbreak of COVID-19

The research team promptly adapted the system and successfully detected SARS-CoV-2 clinical samples during the outbreak of COVID-19 in late 2019. Followed by a Press Conference held in PolyU announcing the technology to public in February.

2021

Technology Transfer from University Scale to Industrial Scale

Jan

First Production Site in PingShan, Shenzhen

Under a collaboration framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical, a factory site is established in PingShan, Shenzhen.

JUL

First Production Site in Hong Kong

EVDL celebrates its first production site with a focus on the device. This site will also act as engineering workshop and main hub for device's R&D work.

2022

A Leap Forward to Further Expansion and Certification

JUN

Device Production Site in Hong Kong is ISO 13485:2016 Certified

Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.

AUG

Signing Ceremony of Strategic Partnership and Opening Ceremony of Production Site in MARS Centre, Hong Kong

EVDL enters into strategic partnership with Shenzhou Space Biotechnology Group (“SBG”) and takes a step forward to clinical trials and product registration. The Company also celebrates the opening of its reagent and microfluidic cartridge production site

Dec

Cartridge Production Site in Hong Kong is ISO 13485:2016 Certified

Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.

2023

Soft Launch

Jan-Dec

Initial Deployment in Different Markets in the Greater Bay Area for Practical Operations

AAMST is now in service at different clinics, private hospitals, laboratories, and more in the Greater Bay Area

Mar

Pingshan, Shenzhen Government and Avalon Group have reached a strategic cooperation intention

Pingshan, Shenzhen Government and Avalon Group will settle the independent research and development project "Avalon Automated Multiplex System" in Pingshan, Shenzhen

2024

Jan

Recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade.

This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.

Apr

Honored with “HKIE MIS Industry Award 2023 - New Industrialization Gold Award”

This recognition is a testament to EVDL's outstanding achievements in the engineering field, further affirming their exceptional performance in enhancing productivity, product quality, and innovation.

May

Cartridge Production Site in PingShan, China is ISO 13485:2016 Certified

Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.

May

Receives support from RAISe+ Scheme by ITC of HKSAR, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem

This recognition affirms AAMST's strengths in terms of I&T component, commercial viability, relevance with government policies and the overall interest of the community.

Milestone

2015

Project Start &
Design Phase

July

Emerging Viral Diagnostics (HK) Limited (“EVDL”) was founded

The core research team is formed by famous scientists, doctors, experienced biotechnologists and engineers as well as technical and technology investors.

Nov

Establishment of Respiratory Virus Research Foundation

HKU and PolyU jointly announced the establishment of “Respiratory Virus Research Foundation”. EVDL and the research team from the Universities immediately kickstarted related virus and translational research work.

2018

Establishment of Prototype Machine &
Biochemistry Reagents

Dec

Successfully Detected Samples

Successful detection of clinical samples in Queen Mary Hospital (QMH). Design of prototype machine and biochemistry reagents established and with more optimization work in the pipeline.

2020

First Introduction of the EVDL System to the Public

JAN

Demonstrated the strength as Platform Technology during outbreak of COVID-19

The research team promptly adapted the system and successfully detected SARS-CoV-2 clinical samples during the outbreak of COVID-19 in late 2019. Followed by a Press Conference held in PolyU announcing the technology to public in February.

2021

Technology Transfer from University Scale to Industrial Scale

Jan

First Production Site in PingShan, Shenzhen

Under a collaboration framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical, a factory site is established in PingShan, Shenzhen.

JUL

First Production Site in Hong Kong

EVDL celebrates its first production site with a focus on the device. This site will also act as engineering workshop and main hub for device's R&D work.

2022

A Leap Forward to Further Expansion and Certification

JUN

Device Production Site in Hong Kong is ISO 13485:2016 Certified

Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.

AUG

Signing Ceremony of Strategic Partnership and Opening Ceremony of Production Site in MARS Centre, Hong Kong

EVDL enters into strategic partnership with Shenzhou Space Biotechnology Group (“SBG”) and takes a step forward to clinical trials and product registration. The Company also celebrates the opening of its reagent and microfluidic cartridge production site

Dec

Cartridge Production Site in Hong Kong is ISO 13485:2016 Certified

Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.

2023

Soft Launch

Jan-Dec

Initial Deployment in Different Markets in the Greater Bay Area for Practical Operations

AAMST is now in service at different clinics, private hospitals, laboratories, and more in the Greater Bay Area

Mar

Pingshan, Shenzhen Government and Avalon Group have reached a strategic cooperation intention

Pingshan, Shenzhen Government and Avalon Group will settle the independent research and development project "Avalon Automated Multiplex System" in Pingshan, Shenzhen

2024

Jan

Recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade.

This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.

Apr

Honored with “HKIE MIS Industry Award 2023 - New Industrialization Gold Award”

This recognition is a testament to EVDL's outstanding achievements in the engineering field, further affirming their exceptional performance in enhancing productivity, product quality, and innovation.

May

Cartridge Production Site in PingShan, China is ISO 13485:2016 Certified

Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.

May

Receives support from RAISe+ Scheme by ITC of HKSAR, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem

This recognition affirms AAMST's strengths in terms of I&T component, commercial viability, relevance with government policies and the overall interest of the community.